News | January 10, 2007

Probe’s First AFib Patients Successfully Treated

Jan. 11, 2007 — First patients have been now been treated with the recently approved SurgiFrost XL, a new minimally invasive surgical probe for treating cardiac arrhythmias. CryoCath Technologies Inc. received FDA 510(k) clearance late in 2006, and the device also received CE mark approval during this same time period.

The first two patients were treated in December Dr. Gary Dworkin from Morton Plant Hospital, Clearwater, FL, and Dr. Saqib Masroor. Dr. Masroor treated a patient with intermittent atrial fibrillation and aortic valve disease. Dr. Dworkin treated a patient with eight years of permanent, symptomatic lone atrial fibrillation. Both patients underwent a standard sternotomy and a complete Cox Maze III lesion set utilizing an epicardially applied SurgiFrost XL without cardiopulmonary bypass support. Both patients left the operating room in sinus rhythm and are doing well.

SurgiFrost XL is a product line extension of CryoCath's SurgiFrost cryosurgical system, which has been the subject of several peer-reviewed publications, including a recently updated independent study pertaining to the ablation of Atrial Fibrillation (AF) using SurgiFrost.

For more information visit www.cryocath.com.

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems| December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems| January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems| November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init